Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity (Q43764129)

26 November 2017

title

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity (English)

1 reference

26 November 2017

Adams JL

1

1 reference

26 November 2017

Boehm JC

2

1 reference

26 November 2017

Gallagher TF

3

1 reference

26 November 2017

Kassis S

4

1 reference

26 November 2017

Webb EF

5

1 reference

26 November 2017

Hall R

6

1 reference

26 November 2017

Sorenson M

7

1 reference

26 November 2017

Garigipati R

8

1 reference

26 November 2017

Griswold DE

9

1 reference

26 November 2017

Lee JC

10

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Bioorganic & Medicinal Chemistry Letters

26 November 2017

published in

1 reference

26 November 2017

volume

11

1 reference

26 November 2017

issue

21

1 reference

26 November 2017

page(s)

2867-2870

1 reference

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Structural basis of inhibitor selectivity in MAP kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

An investigation of imidazole and oxazole syntheses using aryl-substituted TosMIC reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Therapeutic potential of anti-inflammatory drugs in focal stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900570-4

7 January 2021

10.1016/S0960-894X(01)00570-4

Identifiers

DOI

1 reference

26 November 2017

1 reference